Form 4: Cytek Biosciences Director Converts Restricted Stock Units to Common Shares

Jack Ball, a Director at Cytek Biosciences, Inc., acquired 15,706 shares of common stock through the vesting of Restricted Stock Units on June 5, 2025, increasing his direct beneficial ownership to 42,705 shares.

Summary

• Jack Ball, a Director of Cytek Biosciences, Inc. (CTKB), reported a change in beneficial ownership of the company's securities.
• On June 5, 2025, Mr. Ball acquired 15,706 shares of Cytek Biosciences common stock.
• This acquisition resulted from the vesting of 15,706 Restricted Stock Units (RSU Award), where each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, Mr. Ball's direct beneficial ownership of common stock increased to 42,705 shares.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document reports a routine, expected insider transaction (vesting of RSUs) and does not contain information that would significantly alter the company's financial or operational outlook. It is neutral in sentiment.

Positives

• The transaction indicates a routine vesting of previously granted Restricted Stock Units, which is a common form of executive compensation and retention.
• The increase in direct beneficial ownership by a director aligns their interests with those of shareholders.

Future Outlook

This Form 4 filing is a report of a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard insider transaction report within the biotechnology and life sciences industry, reflecting a director's equity compensation vesting. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The transaction reflects a director's increased direct ownership, aligning their interests with shareholders, but is a routine event with minimal direct impact on share price or company operations.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Restricted Stock Units, RSU vesting, Beneficial Ownership, Director stock ownership, Equity compensation